Therapeutic Effect of Pioglitazone in Diabetic Patients with Renal Transplantation

Clinical Trial of Effect of Pioglitazone Therapy on hs-CRP and Lipid Profile in Diabetic Patients with Renal Transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050117413N2

Enrollment

Registered

2014-05-12

Start date

2013-06-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Insulin-dependent diabetes mellitus. Condition 2: Non-insulin-dependent diabetes mellitus. Condition 3: Kidney transplant failure and rejection. Insulin-dependent diabetes mellitus Non-insulin-dependent diabetes mellitus Kidney transplant failure and rejection

Interventions

Intervention 1: Daily one 15 mg Pioglitazone tablet addition to routine insulin therapy for four months. Intervention 2: Daily one placebo tablet addition to routine insulin therapy.

Treatment - Drugs

Placebo

Daily one 15 mg Pioglitazone tablet addition to routine insulin therapy for four months

Daily one placebo tablet addition to routine insulin therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who had undergone kidney transplantation at Labbafinejad hospital within one month after transplantation and diagnosis of diabetes had been confirmed, without age or gender limitation. Exclusion criteria: Cigarette smoker; patients with heart failure FC II & III; hepatitis B and C; GFR less than 30; pregnancy; acute rejection with progressive renal impairment; creatinine more than 1 mg/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood uric acid. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood hs CRP. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood Triglyceride. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood Cholesterol. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Low density lipoprotein (LDL). Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;High density lipoprotein (HDL). Timepoint: Before treatment and six months after treatment. Method of measurement: Laboratory tests.	—

Measure

Time frame

Fasting blood glucose. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood uric acid. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood hs CRP. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood Triglyceride. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Blood Cholesterol. Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;Low density lipoprotein (LDL). Timepoint: Before treatment and after four months treatment. Method of measurement: Laboratory tests.;High density lipoprotein (HDL). Timepoint: Before treatment and six months after treatment. Method of measurement: Laboratory tests.

—

Secondary

Measure	Time frame
Weight. Timepoint: Before treatment and after four months treatment. Method of measurement: Kilograms.;Body mass index. Timepoint: Before treatment and after four month treatment. Method of measurement: kg/m2.;Waste circle. Timepoint: Before treatment and after four months treatment. Method of measurement: Centimeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Karimi Sari

Students’ Research Committee (SRC), Baqiyatallah University of Medical Sciences, Tehran, IR Iran

dr.karimih@yahoo.com+98 21 8126 4354

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026